- 全部删除
- 您的购物车当前为空
Tegoprazan 是一种口服有效的、高选择性胃 H+/K+-ATP 酶 (H+/K+-ATPase) 抑制剂,能够控制胃酸分泌和运动,在体外检测的对猪、犬、人的 H+/K+-ATP 酶的 IC50为0.29-0.52 μM。
Tegoprazan 是一种口服有效的、高选择性胃 H+/K+-ATP 酶 (H+/K+-ATPase) 抑制剂,能够控制胃酸分泌和运动,在体外检测的对猪、犬、人的 H+/K+-ATP 酶的 IC50为0.29-0.52 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 497 | In stock | |
5 mg | ¥ 1,230 | In stock | |
10 mg | ¥ 1,880 | In stock | |
25 mg | ¥ 3,150 | In stock | |
50 mg | ¥ 4,130 | In stock | |
100 mg | ¥ 5,880 | 待询 | |
1 mL x 10 mM (in DMSO) | ¥ 1,050 | In stock |
Tegoprazan 相关产品
产品描述 | Tegoprazan is an orally active, highly selective gastric H+/K+-ATPase inhibitor that controls gastric acid secretion and motility, with an IC50 of 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPase in vitro. |
靶点活性 | H+, K+-ATPase:0.29-0.52 μM |
体外活性 | 方法:Tegoprazan (CJ-12420)(0,0.0005,0.001,0.005,0.01,0.05,0.1,0.5,1,10,100 和,1000 μg/mL,24小时)培养 BMM 细胞,探究其 对 BMM 细胞毒性和一氧化氮 (NO) 产生的影响。 |
体内活性 | 方法:Tegoprazan (CJ-12420)(3,10 mg/kg,口服,5天)治疗幽门结扎大鼠,观察其和埃索美拉唑对幽门结扎大鼠胃酸分泌的影响。 |
分子量 | 387.38 |
分子式 | C20H19F2N3O3 |
CAS No. | 942195-55-3 |
Smiles | CN(C)C(=O)c1cc(O[C@H]2CCOc3cc(F)cc(F)c23)c2[nH]c(C)nc2c1 |
密度 | 1.371 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 22.5 mg/mL (58.08 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容